$DRIO
DarioHealth Corp. Stock $drio

$drio Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000114420417058488 Filed on November 14, 2017

Income Statement

Concept	2017 Q4	2016 Q3
Revenue	$1.580M	$728.0K
YoY Change	88.1%	166.67%
Cost Of Revenue	$1.010M	$652.0K
YoY Change	-17.21%	61.39%
Gross Profit	$570.0K	$76.00K
YoY Change	-250.0%	-158.02%
Gross Profit Margin	36.08%	10.44%
Selling, General & Admin	$2.840M	$2.140M
YoY Change	8.81%	22.29%
% of Gross Profit	498.25%	2815.79%
Research & Development	$850.0K	$659.0K
YoY Change	46.55%	-1.2%
% of Gross Profit	149.12%	867.11%
Depreciation & Amortization	$40.00K	$80.00K
YoY Change	-66.67%	-11.11%
% of Gross Profit	7.02%	105.26%
Operating Expenses	$3.690M	$2.797M
YoY Change	16.04%	15.77%
Operating Profit	-$3.120M	-$2.721M
YoY Change	-12.36%	6.83%
Interest Expense	-$8.800M	$2.110M
YoY Change	515.38%	189.04%
% of Operating Profit
Other Income/Expense, Net		$2.110M
YoY Change		193.87%
Pretax Income	-$11.92M	-$610.0K
YoY Change	127.48%	-66.67%
Income Tax
% Of Pretax Income
Net Earnings	-$11.92M	-$611.0K
YoY Change	127.48%	-66.59%
Net Earnings / Revenue	-754.43%	-83.93%
Basic Earnings Per Share
Diluted Earnings Per Share	-$20.20M	-$2.103M
COMMON SHARES
Basic Shares Outstanding	10.35M shares	5.713M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q4	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.000M	$3.600M
YoY Change	207.69%	80.0%
Cash & Equivalents	$3.718M	$3.339M
Short-Term Investments	$300.0K	$200.0K
Other Short-Term Assets	$153.0K
YoY Change	139.06%
Inventory	$1.184M	$1.100M
Prepaid Expenses
Receivables	$300.0K	$300.0K
Other Receivables	$600.0K	$600.0K
Total Short-Term Assets	$6.046M	$5.600M
YoY Change	105.93%	105.81%
LONG-TERM ASSETS
Property, Plant & Equipment	$869.0K	$1.100M
YoY Change	-3.55%	38.19%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00
YoY Change
Total Long-Term Assets	$911.0K	$1.100M
YoY Change	-2.67%	32.69%
TOTAL ASSETS
Total Short-Term Assets	$6.046M	$5.600M
Total Long-Term Assets	$911.0K	$1.100M
Total Assets	$6.957M	$6.700M
YoY Change	79.67%	88.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.900M	$1.000M
YoY Change	5.56%	11.11%
Accrued Expenses	$428.0K
YoY Change	-31.19%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.015M	$2.000M
YoY Change	3.08%	33.33%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$0.00	$300.0K
YoY Change	-100.0%	-91.67%
Total Long-Term Liabilities	$0.00	$300.0K
YoY Change	-100.0%	-95.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.015M	$2.000M
Total Long-Term Liabilities	$0.00	$300.0K
Total Liabilities	$3.000M	$2.300M
YoY Change	-71.15%	-69.33%
SHAREHOLDERS EQUITY
Retained Earnings	-$70.96M
YoY Change	29.11%
Common Stock	$7.000K
YoY Change	16.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.941M	$4.400M
YoY Change
Total Liabilities & Shareholders Equity	$6.957M	$6.700M
YoY Change	79.67%	88.73%

Cashflow Statement

Concept	2017 Q4	2016 Q3
OPERATING ACTIVITIES
Net Income	-$11.92M	-$611.0K
YoY Change	127.48%	-66.59%
Depreciation, Depletion And Amortization	$40.00K	$80.00K
YoY Change	-66.67%	-11.11%
Cash From Operating Activities	-$2.400M	-$2.720M
YoY Change	29.03%	97.1%
INVESTING ACTIVITIES
Capital Expenditures	-$140.0K	-$160.0K
YoY Change	-65.0%	700.0%
Acquisitions
YoY Change
Other Investing Activities	-$10.00K	-$150.0K
YoY Change	-200.0%	-1600.0%
Cash From Investing Activities	-$140.0K	-$310.0K
YoY Change	-64.1%	1450.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-10.00K	0.000
YoY Change		-100.0%
NET CHANGE
Cash From Operating Activities	-2.400M	-2.720M
Cash From Investing Activities	-140.0K	-310.0K
Cash From Financing Activities	-10.00K	0.000
Net Change In Cash	-2.550M	-3.030M
YoY Change	13.33%	-429.35%
FREE CASH FLOW
Cash From Operating Activities	-$2.400M	-$2.720M
Capital Expenditures	-$140.0K	-$160.0K
Free Cash Flow	-$2.260M	-$2.560M
YoY Change	54.79%	88.24%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	419000	USD
CY2016Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	1113000	USD
CY2016Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	7488000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	48413000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-54960000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-6541000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3872000	USD
CY2016Q3	us-gaap	Revenues Revenues	728000	USD
CY2017Q3	us-gaap	Revenues Revenues	1375000	USD
CY2017Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1099000	USD
CY2016Q3	us-gaap	Gross Profit GrossProfit	76000	USD
CY2017Q3	us-gaap	Gross Profit GrossProfit	276000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	797000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	2797000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	3260000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2721000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2984000	USD
CY2016Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2788000	USD
CY2017Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-678000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5000	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2110000	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-611000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-2978000	USD
CY2016Q3	drio	Deemed Dividend Related To Exchange Agreement DeemedDividendRelatedToExchangeAgreement	0	USD
CY2017Q3	drio	Deemed Dividend Related To Exchange Agreement DeemedDividendRelatedToExchangeAgreement	0	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-876000	USD
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5705229	shares
	us-gaap	Revenues Revenues	1965000	USD
	us-gaap	Revenues Revenues	3592000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2850000	USD
	us-gaap	Gross Profit GrossProfit	742000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2148000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1577000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2450000	USD
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	3194000	USD
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	5707000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3887000	USD
	us-gaap	Operating Expenses OperatingExpenses	7084000	USD
	us-gaap	Operating Expenses OperatingExpenses	12044000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-938000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-31000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	517000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	36000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-560000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-77000	USD
	drio	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	7538000	USD
	drio	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	13469000	USD
	drio	Proceeds From Stock Options And Warrants Exercised ProceedsFromStockOptionsAndWarrantsExercised	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7748000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13469000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	668000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7486000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-697000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	241000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7479000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7026000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3823000	USD
	drio	Deemed Dividend Related To Exchange Agreement DeemedDividendRelatedToExchangeAgreement	455000	USD
	drio	Deemed Dividend Related To Exchange Agreement DeemedDividendRelatedToExchangeAgreement	0	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7746000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.54
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5019918	shares
CY2016	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	605000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-10887000	USD
CY2016	drio	Stock Issued During Period Private Placement Value New Issues March2016 StockIssuedDuringPeriodPrivatePlacementValueNewIssuesMarch2016	828000	USD
CY2016	drio	Issuance Of Common Stock In January2016 To Service Provider IssuanceOfCommonStockInJanuary2016ToServiceProvider	37000	USD
CY2016	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	310000	USD
CY2016	drio	Stock Issued During Period Value Issued To Officer StockIssuedDuringPeriodValueIssuedToOfficer	86000	USD
CY2016	drio	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	210000	USD
CY2016	drio	Deemed Dividend Related To Change In Conversion Term Of Series Preferred Stock Value DeemedDividendRelatedToChangeInConversionTermOfSeriesPreferredStockValue	0	USD
CY2016	drio	Deemed Dividend Related To Exchange Agreement Adjustment DeemedDividendRelatedToExchangeAgreementAdjustment	0	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	-1580000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	906000	USD
	drio	Stock Issued During Period Private Placement Value New Issues January2017 StockIssuedDuringPeriodPrivatePlacementValueNewIssuesJanuary2017	2886000	USD
	drio	Stock Issued During Period Private Placement Value New Issues March2017 StockIssuedDuringPeriodPrivatePlacementValueNewIssuesMarch2017	3855000	USD
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1572000	USD
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	3062000	USD
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	914000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8223000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6520000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5169000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2671000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3339000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	2277000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	406000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	64000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	283000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	191000	USD
	drio	Payments For Proceeds From Acquire Leases Held For Investment PaymentsForProceedsFromAcquireLeasesHeldForInvestment	-1000	USD
	drio	Payments For Proceeds From Acquire Leases Held For Investment PaymentsForProceedsFromAcquireLeasesHeldForInvestment	-3000	USD
	drio	Proceeds From Stock Options And Warrants Exercised ProceedsFromStockOptionsAndWarrantsExercised	210000	USD
	us-gaap	Depreciation Depreciation	155000	USD
	us-gaap	Depreciation Depreciation	273000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	193000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	257000	USD
	drio	Payment For Directors And Management Under Shares For Cash Program PaymentForDirectorsAndManagementUnderSharesForCashProgram	183000	USD
	drio	Payment For Directors And Management Under Shares For Cash Program PaymentForDirectorsAndManagementUnderSharesForCashProgram	154000	USD
	drio	Bank Charges BankCharges	41000	USD
	drio	Bank Charges BankCharges	9000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	6000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2000	USD
CY2016Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	7488000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-7486000	USD
CY2017Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3062000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	914000	USD
CY2017Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1010000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y1M24D
CY2017Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1450000	shares
CY2017Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	3.10
CY2017Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3855000	USD
CY2017Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	36250	shares
CY2017Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.875
CY2016Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	431000	USD
CY2016Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	457000	USD
CY2017Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	430000	USD
CY2017Q3	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	494000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	120000	USD
CY2016	us-gaap	Inventory Write Down InventoryWriteDown	315000	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	DarioHealth Corp.
	dei	Entity Central Index Key EntityCentralIndexKey	0001533998
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	DRIO
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10352424	shares
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	160000000	shares
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	160000000	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10238220	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10238220	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5713383	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5713383	shares
CY2017Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2307654	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2307654	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	265000	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	265000	USD
	drio	Stock Issued During Period Private Placement Value New Issues August2017 StockIssuedDuringPeriodPrivatePlacementValueNewIssuesAugust2017	801000	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	155000	USD
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: left; WIDTH: 0.75in"> <div>NOTE 3: -</div> </td> <td style="TEXT-ALIGN: justify"> <div>UNAUDITED INTERIM FINANCIAL STATEMENTS</div> </td> </tr> </table>   <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0in 0.75in; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The accompanying unaudited interim consolidated financial statements as of September 30, 2017, have been prepared in accordance with U.S. generally accepted accounting principles and standards of the Public Company Accounting Oversight Board for interim financial information. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements. In the opinion of management, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for a fair presentation of the Company's consolidated financial position as of September 30, 2017, and the Company's consolidated results of operations and the Company's consolidated cash flows for the nine months ended September 30, 2017. Results for the nine months ended September 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	6000000	USD
	drio	Registration Rights Waiver RegistrationRightsWaiver	0	USD
	drio	Preferred Stock Issued During Period Private Placement Value New Issues August2017 PreferredStockIssuedDuringPeriodPrivatePlacementValueNewIssuesAugust2017	3711000	USD
CY2017Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	1472000	USD
CY2017Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	USD
	drio	Registration Rights Waiver RegistrationRightsWaiver	650000	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	423000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1878000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		USD
	drio	Increase Decrease In Other Receivables And Prepaid Expense IncreaseDecreaseInOtherReceivablesAndPrepaidExpense	264000	USD
	drio	Increase Decrease In Other Receivables And Prepaid Expense IncreaseDecreaseInOtherReceivablesAndPrepaidExpense	-80000	USD

Files In Submission

Name	View Source	Status
0001144204-17-058488-index-headers.html	Edgar Link	pending
0001144204-17-058488-index.html	Edgar Link	pending
0001144204-17-058488.txt	Edgar Link	pending
0001144204-17-058488-xbrl.zip	Edgar Link	pending
drio-20170930.xml	Edgar Link	completed
drio-20170930.xsd	Edgar Link	pending
drio-20170930_cal.xml	Edgar Link	unprocessable
drio-20170930_def.xml	Edgar Link	unprocessable
drio-20170930_lab.xml	Edgar Link	unprocessable
drio-20170930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv478416_10q.htm	Edgar Link	pending
tv478416_ex10-1.htm	Edgar Link	pending
tv478416_ex31-1.htm	Edgar Link	pending
tv478416_ex31-2.htm	Edgar Link	pending
tv478416_ex32-1.htm	Edgar Link	pending
tv478416_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DRIO
DarioHealth Corp. Stock $drio

2017 Q4 Form 10-Q Financial Statement

#000114420417058488 Filed on November 14, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DRIO DarioHealth Corp. Stock $drio

2017 Q4 Form 10-Q Financial Statement

#000114420417058488 Filed on November 14, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DRIO
DarioHealth Corp. Stock $drio